NCT05247684Active, not recruitingPhase 2
AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
Phase II Clinical Study of AK112, an Anti-PD-1 and VEGF Bispecific Antibody, Alone or in Combination With Chemotherapy for the Neoadjuvant/Adjuvant Treatment of Resectable Non-small Cell Lung Cancer
Source: ClinicalTrials.gov · Last updated 29 Jul 2026
Brief summary (registry, in English)
AK112, alone or in combination with chemotherapy for the neoadjuvant/adjuvant treatment of resectable NSCLC
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (actual)
- First submitted
- 19 Jan 2022
- Start date
- 20 Feb 2022
- Primary completion date
- 18 Aug 2025
- Lead sponsor
- Akeso
- Diseases
- Lung cancer
- NCT number
- NCT05247684
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 90
- From 20 Feb 2022 to the primary completion date, 18 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Is currently participating in a study of an investigational agent or using an investigational device
- Has received a live virus vaccine within 30 days prior to first dose of study treatment
Other illness
- Has an active autoimmune disease that has required systemic treatment in the past 2 years
- Has an active infection requiring systemic therapy
- Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \[qualitative\] is detected)
- Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study
Other
- Is pregnant, breastfeeding, or expecting to conceive or father a child within the projected duration of the study including 120 days following the last dose of study treatment.
Who the study is looking for
- 18 to 75 years old
- Be able and willing to provide written informed consent and to comply with all requirements of study participation
- Histologically confirmed resectable stage II-IIIB NSCLC
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Has adequate organ function
- All female and male subjects of reproductive potential must agree to use an effective method of contraception, as determined by the Investigator, during and for 120 days after the last dose of study treatment.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tianjin Medical University Cancer Institute & Hospital Coordinator of this site? Confirm its status | Tianjin | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.